Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2022-A01421-42 | Other Identifier | IDRCB |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Chronic liver diseases represent a major public health problem and are responsible for more than 150,000 deaths in Europe each year. These diseases are accompanied by symptoms that profoundly alter the quality of life and mainly affect people of working age, leading to a major economic impact.
Coagulation disorders, inflammation and vascular alterations are associated with chronic liver diseases but their role in the onset and/or progression of liver diseases is still not fully understood.
A better understanding of chronic liver diseases and in particular of the factors that play a role in the onset and progression of these diseases would improve patient management and therefore have a positive impact on individuals, but also on the healthcare system and the economy.
Chronic liver diseases represent a major public health problem and are responsible for more than 150,000 deaths in Europe each year. These diseases are accompanied by symptoms that profoundly alter the quality of life and mainly affect people of working age, leading to a major economic impact.
Coagulation disorders, inflammation and vascular alterations are associated with chronic liver diseases but their role in the onset and/or progression of liver diseases is still not fully understood.
A better understanding of chronic liver diseases and in particular of the factors that play a role in the onset and progression of these diseases would improve patient management and therefore have a positive impact on individuals, but also on the healthcare system and the economy.
The main objective is to identify the role of coagulation in the development and progression of chronic liver diseases and their complications.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| controls without liver disease | blood collection on the day of inclusion |
| |
| patients with chronic liver disease without cirrhosis | blood collection on the day of inclusion |
| |
| patients with chronic liver disease with compensated cirrhosis | blood collection on the day of inclusion |
| |
| patients with chronic liver disease with stable decompensated cirrhosis | blood collection on the day of inclusion |
| |
| patients with chronic liver disease with decompensated cirrhosis in the acute phase | blood collection on the day of inclusion |
| |
| patients with chronic liver disease with decompensated cirrhosis and organ failure | blood collection on the day of inclusion |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| biomarker assay | Other | blood sample on the day of inclusion |
|
| Measure | Description | Time Frame |
|---|---|---|
| Activated partial thromboplastin time abnormalities in patients with chronic liver disease at different stages and controls without liver disease | Mesure of activated partial thromboplastin time for each patient at inclusion | at 10 years |
| Factor II abnormalities in patients with chronic liver disease at different stages and controls without liver disease | Mesure of factor II for each patient at inclusion | at 10 years |
| Factor V abnormalities in patients with chronic liver disease at different stages and controls without liver disease | Mesure of factor V for each patient at inclusion | at 10 years |
| Factor VII abnormalities in patients with chronic liver disease at different stages and controls without liver disease | Mesure of factor VII for each patient at inclusion | at 10 years |
| Factor VIII abnormalities in patients with chronic liver disease at different stages and controls without liver disease | Mesure of factor VIII for each patient at inclusion | at 10 years |
| Factor IX abnormalities in patients with chronic liver disease at different stages and controls without liver disease | Mesure of factor IX for each patient at inclusion | at 10 years |
| Factor X abnormalities in patients with chronic liver disease at different stages and controls without liver disease |
Not provided
Not provided
Inclusion Criteria:
Patients with chronic liver disease:
Patients over 18 years of age Patients affiliated with a social security plan or entitled to receive benefits Patients with chronic liver disease or cirrhosis whose diagnosis is based on one or more of the following
Controls without liver disease Patients 18 years of age with no known liver disease Patients who have had blood drawn in the hospital prior to surgery (pre-operative work-up as part of the care process).
Exclusion Criteria:
Common non-inclusion criteria for patients with chronic liver disease and controls without liver disease will be as follows:
Not provided
Not provided
Not provided
Patients over 18 years of age with chronic liver disease Controls without liver disease will be individuals over 18 years of age without liver disease
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Pierre Emmanuel Rautou | Contact | 140875283 | +33 | pierre-emmanuel.rautou@aphp.fr |
| Alix Riescher-Tuczkiewicz | Contact | 140875283 | alix.riescher-tuczkiewicz@inserm.fr |
| Name | Affiliation | Role |
|---|---|---|
| Pierre Emmanuel Rautou | APHP | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Beaujon Hospital | Recruiting | Clichy | France |
Not provided
| ID | Term |
|---|---|
| D013927 | Thrombosis |
| ID | Term |
|---|---|
| D016769 | Embolism and Thrombosis |
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D001800 | Blood Specimen Collection |
| ID | Term |
|---|---|
| D013048 | Specimen Handling |
| D019411 | Clinical Laboratory Techniques |
| D019937 | Diagnostic Techniques and Procedures |
| D003933 | Diagnosis |
Not provided
Not provided
Not provided
Not provided
Not provided
|
Mesure of factor X for each patient at inclusion |
| at 10 years |
| Factor XI abnormalities in patients with chronic liver disease at different stages and controls without liver disease | Mesure of factor XI for each patient at inclusion | at 10 years |
| Fibrinogen abnormalities in patients with chronic liver disease at different stages and controls without liver disease | Mesure of fibrinogen for each patient at inclusion | at 10 years |
| D-dimer abnormalities in patients with chronic liver disease at different stages and controls without liver disease | mesure of D-dimer for each patient at inclusion | at 10 years |
| Protein C abnormalities in patients with chronic liver disease at different stages and controls without liver disease | Mesure of protein C for each patient at inclusion | at 10 years |
| protein S abnormalities in patients with chronic liver disease at different stages and controls without liver disease | mesure of protein S for each patient at inclusion | at 10 years |
| Willebrand factor abnormalities in patients with chronic liver disease at different stages and controls without liver disease | Mesure of plasma Willebrand factor for each patient at inclusion | at 10 years |
| Thrombin generation test abnormalities in patients with chronic liver disease at different stages and controls without liver disease | Mesure of thrombin generation test for each patient at inclusion | at 10 years |
| D011677 | Punctures |
| D013514 | Surgical Procedures, Operative |
| D008919 | Investigative Techniques |